Literature DB >> 33085231

[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].

Jia-Nan Liu1, Zhao-Lei Ma1, Rong-Jian Su2, Ke-Qiang Huang1.   

Abstract

OBJECTIVE: This study aims to study the effect of the enhancer of zeste homolog 2 (EZH2) inhibitor GSK126 on the proliferation and apoptosis of human tongue squamous cell carcinoma cells in vitro and explore its related mechanisms in order to obtain insights into the clinical treatment of tongue squamous cell carcinoma.
METHODS: Different concentrations of GSK126 were applied to CAL-27 cells of tongue squamous cell carcinoma, and the effects of drugs on cell proliferation were detected through methyl thiazolyl tetrazolium (MTT) assay, colony formation assay, and 5-ethynyl-2'-deoxyuridine (EdU) fluorescence staining. Hoechst33342 fluorescence staining and the JC-1 method were used in observing apoptosis. The expression levels of extracellular regulated protein kinases (ERK), phospho-extracellular regulated protein kinases (p-ERK), Bax, Bcl-2, and Cleaved caspase-9 in Cal-27 cells were detected through Western blot.
RESULTS: GSK126 inhibited CAL-27 cell proliferation and promoted apoptosis. GSK126 down-regulated the expression of p-ERK and Bcl-2 and increased the expression of Bax and Cleaved caspase-9 (P<0.05).
CONCLUSIONS: GSK126 can inhibit the proliferation of CAL-27 cells in tongue squamous cell carcinoma and promote its apoptosis, and the related mechanism may be associated with the inhibition of the MEK/ERK signaling pathway and activation of the Bax/Bcl-2 pathway.

Entities:  

Keywords:  GSK126; apoptosis; proliferation; tongue squamous cell carcinoma

Mesh:

Substances:

Year:  2020        PMID: 33085231      PMCID: PMC7573763          DOI: 10.7518/hxkq.2020.05.004

Source DB:  PubMed          Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi        ISSN: 1000-1182


  21 in total

Review 1.  Apoptosis and apoptotic body: disease message and therapeutic target potentials.

Authors:  Xuebo Xu; Yueyang Lai; Zi-Chun Hua
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

Review 2.  BAX to basics: How the BCL2 gene family controls the death of retinal ganglion cells.

Authors:  Margaret E Maes; Cassandra L Schlamp; Robert W Nickells
Journal:  Prog Retin Eye Res       Date:  2017-01-04       Impact factor: 21.198

3.  A simple novel prognostic model for early stage oral tongue cancer.

Authors:  A Almangush; R D Coletta; I O Bello; C Bitu; H Keski-Säntti; L K Mäkinen; J H Kauppila; M Pukkila; J Hagström; J Laranne; S Tommola; Y Soini; V-M Kosma; P Koivunen; L P Kowalski; P Nieminen; R Grénman; I Leivo; T Salo
Journal:  Int J Oral Maxillofac Surg       Date:  2014-11-11       Impact factor: 2.789

Review 4.  Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review.

Authors:  Aisha A Hussein; Marco N Helder; Jan G de Visscher; C René Leemans; Boudewijn J Braakhuis; Henrica C W de Vet; Tymour Forouzanfar
Journal:  Eur J Cancer       Date:  2017-06-24       Impact factor: 9.162

Review 5.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

Review 6.  Enhancer of zeste homolog 2 (EZH2) inhibitors.

Authors:  Nitya Gulati; Wendy Béguelin; Lisa Giulino-Roth
Journal:  Leuk Lymphoma       Date:  2018-02-23

7.  IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact.

Authors:  Benjamin Bonneau; Hideaki Ando; Katsuhiro Kawaai; Matsumi Hirose; Hiromi Takahashi-Iwanaga; Katsuhiko Mikoshiba
Journal:  Elife       Date:  2016-12-20       Impact factor: 8.140

8.  IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC.

Authors:  Leong-Perng Chan; Cheng Liu; Feng-Yu Chiang; Ling-Feng Wang; Ka-Wo Lee; Wan-Ting Chen; Po-Lin Kuo; Chia-Hua Liang
Journal:  Oncotarget       Date:  2017-04-07

9.  The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.

Authors:  Zhongwu Li; Yanling Wang; Jing Qiu; Qiang Li; Chunping Yuan; Wei Zhang; Dongmiao Wang; Jinhai Ye; Hongbin Jiang; Jianrong Yang; Jie Cheng
Journal:  Oncotarget       Date:  2013-12

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.